This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk00: Ladies and gentlemen, thank you for standing by. Welcome to the MediWound fourth quarter 2020 conference call. I would now like to turn the call over to your speaker, Mr. Jeremy Feifer. Thank you. Please go ahead, sir.
spk03: Thank you, Natalia, and good morning, everyone. Earlier today, MediWound issued a press release announcing financial results and provided a business update for the fourth quarter and year-end 2020. You may access that release on the company's website under the Investors tab. With us today are Sharon Malka, Chief Executive Officer of MediWound, and Boaz Gor-Levi, Chief Financial Officer. Following management's prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session relating to MediWound's expected future performance, future business prospects, or future events or plans, are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors beyond the control of Meadowood. The company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to cautionary notes set forth in today's press release and as well as the risk factors set forth in MediWound's annual report filed with the SEC for factors that could cause actual results to differ materially from those anticipated in the forward-looking statements. This conference is the property of MediWound, and any recording or rebroadcast is expressly prohibited without the written consent of MediWound. Now I would like to turn the call over to Sharon Malka, Chief Executive Officer of MediWound. Sharon? Thank you, Jeremy.
spk07: Thank you, Jeremy. Good morning to our listeners and in the U.S. listeners and good afternoon to our listeners in Israel. Welcome to Mediwound's fourth quarter and full year 2020 conference call to discuss our financial results and business highlights. We are very proud of our results in 2020, especially given the challenges of COVID-19 pandemic. Despite those significant challenges, our team have presented the highest commitment and executed across the board, clinically, operationally, and financially. We are very pleased with the fourth quarter financial results as we continued generating strong product revenue growth compared with the prior year. We have delivered on a BLA filing for NexoBREED. We advanced our Phase 2 adaptive design study of SKRX and we initiated a new clinical development program of our product candidate, 005, to treat non-melanoma skin cancer. Our fourth quarter results demonstrate the significant progress we've made in 2020 on several key metrics that give us confidence regarding our long-term growth profile and the potential for significant growth acceleration as we move into 2021, and we look forward to achieving multiple significant catalysts in 2021. Let me start with a quick review of Nexovrid before providing more details on SKRx development program and our new and exciting non-melanoma skin cancer clinical development program. We are pleased to see product revenue growing and the global expansion of NexoBridge to new territories. From an operational standpoint, we continue to generate strong revenue growth with NexoBridge, aided by our NexoBridge strategic partnership with BARDA and our continued expansion globally through distribution agreements with partners who are leaders in each of their countries. Following the BLA submission for Nexobrid, we look forward to potentially adding one more major country offering Nexobrid this year, the U.S. We continue to work together with BARDA, VeriCell, and the FDA during the regulatory review process as we prepare for our PADUFA goal date of June 29th as our U.S. commercial partner for Nexobrid, VeriCell, actively preparing for commercial launch. As a reminder, we achieved several additional accomplishments with NexoBrit this year. The DETECT study, including its long-term follow-up, was completed, and the 24-month patient follow-up safety data was comparable across all arms. We completed the patient enrollment stage in the NexoBrit pediatric study, expecting top-line data in the second half of 2021, and continue to enroll burn patients in the next expanded access program, enabling U.S. burn specialists and their teams to generate hands-on experience with NexoBridge. Moving to our S-CAREX development programs, we continue to actively recruit patients for our U.S. Phase II adaptive design study for the treatment of venous leg ulcers. Recently, we have adjusted enrollment target of the study to 120 patients down from the 174 originally planned. The sample size adjustment was supported by in vivo trial results, which I will elaborate on shortly. as well as statistical powering assessment of our prior Phase II study with first-generation SCRx. The current design enables us to accelerate study completion while keeping the option to increase the sample size, if required, based on the interim assessment. We expect to complete patient enrollment by year-end 2021 and reiterate our expectation for the interim assessment around mid-year 2021. We successfully completed a preclinical study designed to evaluate the debridement efficacy of SKRx in a post- and hard-to-heal wound model and compare its efficacy with an FDA-approved and commercially available collagenous enzymatic debridement agent. conducted in collaboration with the U.S. Research Center, concluded that Escarex treatment was more effective than the commercially available collagenase agent in removing Escares in this model. And the results from this study are expected to be published in a peer-reviewed journal in the first half of 2021. We continue to explore Escarex pharmacological effects and its potential clinical benefits associated with chronic wound management. We submitted a protocol to the FDA and are preparing to initiate a pharmacology study in the first half of 2021. The study is an open-label, single-arm study assessing the pharmacological effect of SCRx in up to 15 patients with both VLUs, venous leg ulcers, and DFUs, diabetic foot ulcers. This study will teach us what is happening in the wound bed during and after debridement with SKRx. In particular, it will enable to assess the effect on reduction in biofilm burden, reduction in inflammation, and healing progression. We expect data from this study in the second half of 2021. To provide a more in-depth review of our SCRx Clinical Development Program, we plan to host an analyst day in the coming weeks. This event will feature multiple speakers who will discuss the current wound care treatment landscape in the U.S., the particulars of our ongoing clinical studies, the in vivo comparator study, and the biofilm opportunity. Please stay tuned for more details soon, and we look forward to your participation. We are also exploring pipeline opportunities and are excited with the initiation of our new clinical development program for the treatment of non-melanoma skin cancer with our product candidate under development, 005. The initiation of this new program represents an important step in our strategic evolution to leverage our innovative enzymatic platform technology to pioneer solutions for unmet medical needs. 005 is a biological product candidate for topical self-administration, which is based on the same active ingredients as Nexobrid and Escarex products, a concentrate of proteolytic enzymes and rich in bromelain. The company's decision to investigate 005 and move it into human trials for non-melanoma skin cancers is based on positive preclinical studies combined with existing scientific evidence demonstrated the bromelain anti-carcinogenic activity, which reflected by inhibition of cancer cell growth via apoptotic cascade and reduction of tumor formation and volume. The preclinical studies were performed in parallel with successful clinical case studies that demonstrated the product candidate's safety and its pharmacology effect, suggesting that 005 might have a role in treatment of low-risk non-melanoma skin malignancies. Non-melanoma skin cancers, including basal cell carcinoma, BCC, are by far the most common of all types of cancers and represent a significant potential market opportunity. According to the American Cancer Society, BCC is the most diagnosed skin cancer in the United States, with approximately 4.3 million diagnosed cases every year, increasing 5% to 8% a year as a result of increased sun exposure greater life expectancy, and better skin cancer detection. There is a need for more effective, safer topical treatment options in low-risk BCC, and we believe that 005 has the potential to be an effective, non-invasive treatment for BCC without the side effects associated with the current topical therapies and their longer treatment duration. We plan to initiate a Phase 1-2 open-label randomized clinical study of 005 in BCC designed to evaluate safety and tolerability using different schedules of administrations, as well as to provide us with a preliminary evaluation of its efficacy as measured by the percentage of target lesion with complete histological clearance. The study will enroll up to 32 patients with histological confirmed superficial or nodular BCC and will be conducted at three leading clinical centers in the U.S. In parallel, an investigator-initiated Phase II trial will be conducted at the Soroka Medical Center in Israel, designed to evaluate the safety and efficacy of 005 in removing non-melanoma skin cancer and precancerous lesions in up to 50 patients, including actinic keratosis, basal cell carcinoma, and squamous cell carcinoma. We expect that data from both studies will be generated by ERA in 2021. In summary, we believe that 0.0.5 represents a de-risk opportunity, leveraging our lead compound used in SCRX and NexoBREED, targeting a sizable market with a clear unmet need and requires relatively low development costs. We are pleased with our achievements so far and looking forward to a pivotal year in 2021. Now, I would like to turn the call over to Boaz for a summary of our financials.
spk06: Boaz? Thank you, Sharon. Good morning to our U.S. listeners and good afternoon to our listeners in Israel. First, I'm proud with our 2020 financial results, which our teams executed in high uncertainty and fast-changing environment. We have continuously improved our internal measures to control and monitor our expenses and investments, while maintaining flexibility for additional cost reduction in the future if necessary. We are very pleased with our next hybrid revenue growth, driven primarily by the deliveries of emergency stockpile to Barada, Europe cells, and our global expansion with new countries added in 2020, resulting in cash inflow to further support our balance sheet and clinical development programs. I would like now to provide you with an update on our financial results for the first quarter and full year of 2020. Revenues for the first quarter of 2020 were $6.7 million, compared with the $5.4 million for the first quarter of 2019, an increase of 23%, primarily driven by BARDA emergency stockpile procurement of $1.8 million, and partially offset with a $0.5 million decrease in revenues from development services. We generated strong revenue growth as sales of products in the first quarter of 2020 were 2.8 million, reflecting an increase of 155% in comparison to the first quarter of 2019, primarily driven by BARDA emergency stockpile procurement. Gross profit was 2.3 million compared to a gross profit of 1.1 million for the first quarter of 2019. Gross margin for the sales of product was 56% in comparison to 32% for the fourth quarter of 2019. The increasing gross margin from sales of product is a result of our top-line increase in the fixed nature of our costs. Research and development expenses net of participation were 2.2 million compared with the 1.7 million for the fourth quarter of 2019. The increase was primarily due to the ongoing S-Correct clinical development program. Selling general and administrative expenses were $2.5 million, stable with a $2.4 million for the first quarter of 2019. Operating loss was $2.4 million, compared with an operating loss of $3.1 million in the first quarter of 2019. The company posted a net loss of $1.7 million, or $0.06 per share, for the fourth quarter of 2020, compared with a net loss of $3.4 million, or $0.13 per share, for the fourth quarter of 2019. Adjusted EBITDA, as defined below, for the fourth quarter of 2020, was a loss of $1.8 million, compared with a loss of $2.4 million for the fourth quarter of 2019. I'd like now to turn to the full year 2020 financial results. Revenues for the year ended December 31st, 2020, or 21.8 million, compared with the 31.8 million for the year ended December 31st, 2019, which included a 17.5 million upfront payment from the VeriCell License Agreement for NexoBridge. Sale of products for the full year of 2020, or 7.8 million, reflecting an increase of 170% compared to the full year of 2019, primarily driven by BARDA emergency stockpile procurement. Gross profit was $7.5 million, compared with a gross profit of $19.9 million for the year ended December 31, 2019. Excluding the $17.5 million upfront license payment, net of $0.7 million of deal-related expenses, Gross profit for the year ended December 31, 2019 was $3.1 million. Gross margin from sales of products for the full year of 2020 was 60% in comparison to 35% for the full year of 2019. Research and development expenses for the full year of 2020 were $7.7 million compared with the $5 million in the prior year period. The increase was primarily as a result of our U.S. Phase II Adaptive Design Study of S-Corex, and a non-cash increase in participation from the Israeli Innovation Authority grant recorded in 2019. Selling, general, and administrative expenses were $8.7 million, compared with $9.3 million for the year ended December 31, 2019. The decrease was primarily due to the company's headquarters restructuring in Europe. The company's net loss in 2020 was $9.2 million, or a loss of $0.34 per share, compared with a net profit of $5 million, or a profit of $0.18 per share for the same period in 2019, which included a $17.5 million upfront license payment and $1.7 million of deal-related expenses. Excluding the upfront license payment net of deal-related costs, net loss for the year ended 2019 was $10.8 million, or $0.40 per share. Adjusted EBITDA was a loss of $6.4 million, compared with a profit of $8 million for the year ended December 31, 2019, which included the upfront payment of $17.5 million from the various licensing agreements, net of royalty payment of $0.7 million. The company had $21.6 million in cash and short-term investments as of December 31, 2020, compared with the $29.5 million as of December 31, 2019, with no debt. The company utilized $7.9 million in cash to fund its ongoing operating activities and repayment of contingent liabilities during 2020, done from its cash guidance for 2020 of $8 to $10 million. We expect to continue investing in SKRX and 005 clinical development programs supported by the expected cash inflow from NexoBridge. As a result, the company expects its cash use for operating activities in 2021 to be in the range of $5 to $7 million. With that, I've concluded the financial overview and will now turn the call back over to Sharon. Sharon?
spk07: Thank you, Boaz. As you can see, we have several tremendous opportunities before us. We will continue our commercialization activities with our partner, VeriCell, and we look forward to working with FDA for the regulatory review process for NexoBREED. We are actively recruiting patients for the SCRx Phase II Adaptive Design Study, and we are excited to initiate our new clinical program in non-melanoma skin cancer. With that, I conclude our prepared remarks, and it is now my pleasure to open the call for your questions. Operator?
spk00: Ladies and gentlemen, at this time, if you would like to ask a question, please press star, then the number 1 on your telephone keypad. Again, to ask a question, please press star 1. We will pause for just a moment to compile the Q&A roster. Your first question is from the line of Ryan Zimmerman with BTIG.
spk02: Thank you. Good afternoon, Sharon and Boz. Thank you for taking the questions and congrats on all the progress. Maybe to start on SCRX, since it is really, you know, the key milestone or kind of key value creation event this year, not to take away any thunder from the analyst day, but, you know, what can we expect in terms of, you know, what you may lay out at the analyst day to give investors a sense of kind of your thinking on SKRX and any other, you know, things you can point to in terms of your confidence around timing of both the interim analysis and the broader trial design.
spk07: Thank you for your question, Ryan. First of all, as you know, we remain excited. about the S-CAREX opportunity and believe it may become a game changer if successful develop addressing a significant unmet medical need with a sizable market opportunity. What we can expect for 2021 in this program is as follows. First, we do have the ongoing phase two adaptive design study where we anticipate the interim assessment around mid-year and the completion of patient recruitment towards the end of the year. the new design of the study after the reduction in sample size enable us to accelerate the program and complete patient enrollment by year end 2021 while keeping the option to increase sample size based on the interim assessment and given the historical data, we are confident with the new sample size. In addition, we plan to initiate a pharmacological study in this quarter, and we anticipate to generate data from this study towards the second half of this year.
spk02: Okay. Appreciate that. And maybe, Boaz, for you, in terms of the cadence of BARDA procurement, is there any color you can give around kind of your expectations for 2021 for around how BARDA may choose to procure NexoBrid over the coming quarters. Thank you.
spk06: Thank you, Ryan, for the question. We're expecting to have the BARDA procurement throughout the quarters and complete it by year-end. And probably I would look at it on a pro-rated basis throughout the quarters, give or take. Okay.
spk02: Thank you for taking the question.
spk00: Your next question is from the line of Kevin the Teeter with Oppenheimer.
spk04: Hey, great. Thanks for taking my question, guys. And, yeah, congrats. Everything's moving on really quickly. And so a few questions for us on the non-melanoma skin cancer program. You know, thanks for the additional detail on study design. Can you comment on you know, how many different dosing regimens you may be looking at or able to capture data on that 32 patients. And, you know, it seems like that study is going to enroll, you know, quite quickly. Just, you know, any general comments on how to think about, you know, relative access to patients and pace of enrollment, you know, for this patient population as a comparison to your experience with ASCOREX? Thanks.
spk07: Okay. Thank you very much for your question. I will start with the BCC. And while MediWound's primary focus remains the continued growth of the company and advancement of the Nexo with an Escarex program, the company is continuously exploring potential clinical application of its lead compound and its energetic product candidates to our portfolio. Our platform technology of the pharmaceutical grade bromelain provides us with the optionality and potential for future products and indications for which we already completed in the last year preclinical and proof-of-concept studies. We decided to pursue the non-melanoma skin cancer opportunity due to the limited treatment option and the clear unmet need. And we believe that overall the development plan is de-risk as it is based, first of all, on the same active substance as Nexobridge and Escarex. It's for topical application and has supporting evidence, including clinical case studies, while the development plan has relatively low development costs. Specifically to the Phase I-II study that we plan in the U.S., the study will enroll up to 32 patients, with histologically confirmed superficial or nodular BCC, and it will be comprised of two cohorts of 16, while we will analyze the safety and tolerability data after the first cohort and adjust accordingly.
spk04: Great. And with regard to the clinical case studies and preclinical data on BCC that you highlight in your prepared comments, what we see in the with regard to either medical meetings or the upcoming analyst day, you know, on some of that data and the product profile?
spk07: Yes. So basically the main goal of a physician in this indication is to remove this cancer, to remove this lesion. So what we saw or show in the preclinical data as well as in the clinical evidence with the cancer cell line, we demonstrated inhibition of cancer cell growth via apoptotic cascade. In addition to that, we did see that bromelain, the active ingredients in our mixture of proteins, has reduction in proliferation process, resulting with reduction in tumor formation and tumor volume. We also saw the same effect in case studies, in clinical case studies we conducted, and this is exactly what we now want to evaluate. In addition to safety and tolerability of different administration schedules, we believe that this initial study, a proof-of-concept study, will provide us with a preliminary evaluation of the efficacy of this product in BCC and as measured by the percentage of the target lesion removed and confirmed by histological clearance.
spk04: Very helpful. Thanks so much for taking my questions.
spk00: Your next question is from the line of Josh Jennings with Cowen.
spk01: with the S-Corrects query, just thinking about urinalysis at mid-year, how would you have investors think about the potential outcomes there? You downsize the patient enrollment size to 120, urinalysis will hold 60 patients. If the Data Safety Monitoring Board gives the green light for the trial to continue, it's our assumption that that would, you know, provide us an efficacy signal, and we'd interpret that very positively. We just want to make sure we understood the setup correctly, and how would we have investors think about early-term analysis in the trial proceeding as is, or even with an increase in patient numbers?
spk07: Yeah. Thank you for the question, Josh. As I mentioned before, the current design of this study, the adaptive design of the study, and the revised or modified sample size enable us to, on one hand, accelerate the program and complete patient enrollment by year-end 2021, while keeping the option to increase the sample size based on the interim analysis. And specifically to the interim analysis, based on the interim analysis, we will have one of the following outcomes as will be recommended by an independent statistician of the DMC. One is whether the study is futile, i.e., to stop the study. Second alternative is to continue as planned with the original sample size, which is 120 patients. This will provide us with a clear signal about the potential success to meet the primary endpoint or increase the sample size. We have that option to increase the sample size up to 160 patients overall, means additional 40 patients. And based on this recommendation, it will give a signal towards the potential success of this study, assuming the residual balance of the patient will behave the same like the ones that are already treated. The sample size will be conducted after we will treat about 80 patients out of the 120.
spk01: That's special and I appreciate it. The question on Nexabrid, I think you referenced in the call that you're working with the FDA on the Nexabrid BLA. Can you just talk to us about your confidence level that the FDA will meet the June PDUFA date given the COVID capacity constraints at the agency that we've heard buzzing around?
spk07: This is very difficult to estimate. As you know, we remain excited about the next opportunity and the FDA potential approval of this product. MediWound is continuing to work closely with the FDA during the review of this biologic license application. We are aware that in many instances across the industry, the FDA's facilities inspection schedule has been affected by the COVID-19-related travel restriction. However, at current, our PADUFA goal date remains June 29, 2021. Excellent.
spk01: One question on MWPC-005. Thanks for all the details and talking about the patient opportunity. Can you talk about, help us understand the topical therapy market as it stands today, what topical therapies have been approved and commercialized, and what's the size of the topical therapy segment for BCC?
spk07: So what I can share with you is the initial insights from an initial market assessment we conducted in the U.S. by a third party. What we know is as follows. First of all, the BCC is the most diagnosed skin cancer in the U.S. with about 4.3 million diagnosed cases every year, while it's increasing because of all the parameters I mentioned before, the option to diagnose it, the sun exposure, et cetera. We know that nodular and superficial are the most. common subtype of BCC account for about 90% to 95% of overall cases. And the unmet need for this low-risk skin malignancies is due to the fact that the current or standard of care or the standard of care for low-risk patients usually tumor eradication by either standard surgical excision or in some cases, mainly in the superficial one, or the ineligible operative patient, is to use any kind of topicals. The topical treatments, which are mainly two, one is the 5-FU, a chemotherapy, and the second one is Imicrimod. It is a generic product. Are used specifically in BCC patients, but have limited use, and are reserved for surgery-ineligible patients usually. And they have several drawbacks, which include longer treatment duration. It requires more than six weeks of daily application. It's low efficacy. And, of course, because of the chemotherapy, the side effects associated with those therapies. That is why we believe that there is a need, clear need, for more effective, safer, topical agent in low-risk superficial BCC and surgery in eligible patients.
spk01: Thank you. And just one last question, just on the pipeline. Historically, you haven't talked about MWPC003. in a couple of years, I believe, but that was, I think, for the indication was to contracture, you know, scar formation, chronic disease. Any update there or any other pipeline candidates that are under development that you haven't talked about recently that there are updates for? Thanks for taking all my questions.
spk07: Thank you for this question. As I mentioned before, we, as a company, are continuously exploring potential clinical application of our lead compound in order to add additional product to our pipeline portfolio. As you know, our platform technology of the pharmaceutical grade bromelain, which is basically a concentrate of proteolytic enzymes enriching bromelain, provides us with optionality and potential for future product and indication, as you mentioned before. like scars, like connective tissue disorder. And for all those potential indications and potential products, we already completed the preclinical development in the toxicology study for the injectable form and for the topical application. And we completed during 2020 proof of concept studies. We concluded to move forward into the clinical stage. with 005 as the first new indication to our portfolio. And while we are, while the primary focus, of course, remains the continued growth through the advancement of Nexo with NS-CAREX.
spk01: Thanks again. Thanks, Rob.
spk00: Again, ladies and gentlemen, to ask a question, please press star 1 on your telephone keypad. Again, that is star 1. Your next question is from the line of Swayam Pakula Rama with CANS.
spk05: Thank you. It's RK from Hixley-Wainwright. Good morning, Sharon and Boaz. A couple of quick questions. The next hybrid study in children, you're anticipating to put out some data in the second half of 2021. So how should we think about this study, would this help you or sufficient to get a pediatric indication in the United States and Europe?
spk07: Thank you for your question. We anticipate, following the completion of the recruitment, we anticipate to report the top-line results from this study, which will include the 12-month follow-up safety data during the second half of 2021. This study basically is aimed or intended to ask for label extension both in Europe and in the U.S. And based on our experience with the DETECT study with the FDA, we believe that we can be in a position to submit a pediatric indication expansion for NexoBridge based on the 12-month follow-up data, while the 24-month follow-up data can be a post-marketing submission. We have to remember that as opposed to Europe, in the U.S. we are excluded from the pediatric investigational plan, and this study was approved and designed together with both EMA and the FDA.
spk05: Okay, thank you for that. And then regarding additional geographies where you could potentially expand NexoBRED commercialization, Can you give us the progress in any of these countries that you've already signed up distribution agreements over the last year? You know, France, Switzerland, and also the Middle Eastern market.
spk07: Yeah. So, in June 2021, we signed several distribution agreements in major countries. I think that we can split it into two. First, some additional countries in EU, which is part of our hybrid model to basically have a growth of next of breed and outreach and next of breed in new and additional territories within the European country, leveraging our existing approval. We do have a marketing approval for all EU countries. And with that, we sign with, as you said, France, Switzerland, the Baltic countries, Greece, and additional countries in the Europe. Within those countries, the distributors already have the marketing approval. All they need to get is basically market access and to launch a product, and we believe that during 2021, we will see in some countries already launch of this product. Moving to international countries or other territories, We signed several distribution agreements while we focus in three main continents, the Latin America area, the CIS, Russia and Ukraine, and, of course, Asia Pacific. We anticipate to have additional approvals during 2021, given the review process in some countries. And we recently signed also a distribution agreement in UAE, in United Arab Emirates, which provide us with, you know, open up new markets, which is the Middle East market and the African market, and we believe can, you know, generate more growth to next-of-breed activity.
spk05: Thank you, gentlemen. Thanks for taking my questions.
spk00: I am showing no further questions at this time. I would now like to turn the conference back to Sharon Malka.
spk07: Thank you, everyone, for joining us today. We look continuing to execute on our strategy and bringing new therapies to market and to updating you again on our next update call. Thank you and have a great day. Bye-bye.
spk00: Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.
Disclaimer